Enveric Biosciences Q1 net loss narrows to $1.6M; cash position improved to $10.3M

Enveric Biosciences, Inc.

2026-Q1 EPS reported -$1.08

Net loss $1.6M ($1.08 loss per share) vs $2.2M ($14.58) in Q1 2025; cash $4.9M at March 31.
Raised gross $2.8M in Q1; subsequent $1.5M from warrant exercises and $5M upfront from $13.9M private placement.
As of May 15, cash balance approx $10.3M; expects to fund EB-003 activities into Q1 2027.
Advancing EB-003 toward IND; new preclinical data including PTSD model with rapid fear response reduction.
AbbVie withdrew PGR petition against Enveric patent covering bretisilocin; strengthens IP portfolio.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.